Díaz-Aragón A, Álvarez-López H, Ruiz-Gastélum E

Idioma: Inglés [English version]
Referencias bibliográficas: 19
Paginas: s157-159
Archivo PDF: 230.16 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Brouwers MCGJ, van Greevenbroek MMJ, Stehouwer CDA, de Graaf J, Stalenhoef AFH. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol. 2012; 8: 352-362.

2. Mata P, Alonso R, Ruíz-Gracia A, Díaz-Díaz JL. González N, Gijón-Conde T et al. Hiperlipidemia familiar combinada: documento de consenso. Aten Primaria. 2014; 46: 440-446.

3. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet. 2004; 36: 371-376.

4. Laurila PP, Soronen J, Kooijman S, Forsstrom S, Boon MR, Surakka I et al. USF1 deficiency activates brown adipose tissue and improves cardiometabolic health. Sci Transl Med. 2016; 8: 22-41.

5. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gomez Perez FJ, Rull JA et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001; 42: 1298-1307.

6. Huertas-Vazquez A, Aguilar-Salinas C, Lusis AJ, Cantor RM, Canizales-Quinteros S, Lee JC et al. Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler Thromb Vasc Biol. 2005; 25: 1985-1991.

7. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003; 23: 1289-1294.

8. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992; 70: 733-737.

9. Veerkamp MJ, de Graaf J, Bredie SJH, Hendricks JCM, Demacker PNM, Stalenhoef AFH. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families. Arterioscler Thromb Vasc Biol. 2002; 22: 274-282.

10. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet. 2004; 13 Spec No 1: R149-R160.

11. Naukkarinen J, Ehnholm C, Peltonen L. Genetics of familial combined hyperlipidemia. Curr Opin Lipidol. 2006; 17: 285-290.

12. Paramsothy P, Knopp R, Bertoni AG, Tsai MY, Rue T, Keckbert SR. Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis (MESA). Metabolism. 2009; 58: 212-219.

13. Veerkamp MJ, de Graaf J, Stalenhoef AFH. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2005; 25: 1026-1031.

14. Teslovich TM, Musumuru K, Smith AV, Edmonson AC, Stylianou IM, Koseki M et al. Biological, clinical, and population relevance of 95 loci for blood lipids. Nature. 20105; 466: 707-713.

15. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45 (11): 1274-1283.

16. Sharifi M, Futema M, Nair D, Humphries SE. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep. 2019; 21 (6): 43.

17. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013; 381: 1293-1301.

18. Futema M, Bourbon M, Williams M, Humphries SE. Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. Atherosclerosis. 2018; 277: 457-463.

19. Mickiewicz A, Futema M, Cwiklinska A, Kuchta A, Jankowski M, Kaszubowski M et al. Higher responsiveness to rosuvastatin in polygenic versus monogenic hypercholesterolaemia: a propensity score analysis. Life (Basel). 2020; 10 (5): 73.